Merck has received a complete response letter from the US Food and Drug Administration (FDA) seeking to add cardiovascular outcomes data from the TECOS study to the labels of J Januvia (sitagliptin), Janumet (sitagliptin and metformin), and Janumet XR (sitagliptin and metformin extended-release).
News from Twitter
Looking forward to meeting you all at #BIO2017 San Diego, June 19-22, 2017. Let's schedule: 1 (800) 445-1839 // +41 22 518 2100
Scopis launches mixed reality spinal surgery navigator with Microsoft’s HoloLens captis.com/scopis-la…
One Drop, MannKind ink partnership for connected, inhaled diabetes tech captis.com/?p=33587
Our very best and up-to-date selection of healthcare Industries' News (Products, Markets, Companies, R&D, Technology, Opportunities, Investment & Finance...).
Read at Healthcare News